Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

The United States Blind & Shade Manufacturing Market: 2019 Research Report – California Averages $37,423 in Payroll Per Employee –



Reading Time: 4 minutes

and Shade Manufacturing – The 2019 U.S. Market Research Report”

report has been added to’s

This report is an in-depth evaluation of the industry in the United

The report is based on extensive and comprehensive business surveys.
This report is utilized for a range of strategic purposes, including
benchmarking, due diligence, cost cutting, planning, evaluating
opportunities, forecasting, streamlining, and gap analysis.

The report includes over 100 insightful data sets, such historical and
forecasted industry sales, operating expense details, product line
breakdown, financial ratios, benchmarks, wages, profitability,
organizational analysis, revenue per employee, state statistics, price
inflation, consolidation analysis, firm dynamics, pay ranges for
different roles, firm size data, employment, and much more.

Review the table of contents or download a sample report to see the
broad and in-depth insights, which leaders have come to depend on for
their research, strategic and benchmarking needs.

Report Highlights


In 2018, industry sales were $2.4 billion

Purchase now for historical and forecasted market size


Over the past 3 years, the industry has grown at an annual rate of 2.4%

Purchase now for historical, annual and forecasted growth rates


There are 317 companies in the industry

Learn more about the historical and forecasted industry composition


In 2018, the average sales per company was $7.7 million

Purchase now for historical and forecasted sales per company


2019 forecasted inflation is 0.9%

Purchase now for historical industry inflation and the 5-year forecast


Companies average a Fixed Asset Turnover ratio of 2.8

Benchmark nine other important financial ratios


Employee productivity is $215,722

Purchase now for historical and forecasted employee productivity


2.7% of expenses are spent on health insurance

Benchmark against 24 other expense categories


In 2018, industry operating expenses grew 4.1%

Purchase now for historical and forecasted OPEX


In 2018, payroll per employee was $45,706

Get the full picture with historicals and the 2019 and 5-year forecasts


California averages $37,423 in payroll per employee

Purchase now for payroll stats on other states


4.2% of employees in the industry are in management positions

Benchmark against 13 other job categories


The average industry hourly pay for office and administrative jobs is

Purchase now for the bottom 10%, 25%, average, top 75% and 90% pay
ranges in 14 job categories

The above highlights represent a small fraction of what you will
find in this report

Key Topics Covered

Page 1-2 – Report Overview

Page 3 – Industry Overview

  • Methodology
  • Industry Definition & Examples

Page 4 – Industry Snapshot – Revenue & Growth

Page 5 – Industry Snapshot – Costs & Profitability

Section One


Page 7 – Industry Growth Details

  • Industry Revenues
  • Firms
  • Establishments
  • 2010-2018 Historical Figures
  • Forecasts 2019 and the Next 5 Years

Page 8 – Growth Benchmarks

  • Revenues per Firm
  • Revenues per Establishment
  • Establishments per Firm
  • 2010-2018 Historical Figures
  • Forecasts 2019 and the Next 5 Years

Page 9 – Breakdown of Product Lines

  • Percentage of Revenue from Product Lines

Page 10 – Product Line Growth

  • 4 Year CAGR

Page 11 – Manufacturing Subsector Growth

  • Sales and 5 Year CAGR

Page 12 – Income vs. Revenue Growth Matrix

  • Service Subsectors vs. Industry

Page 13 – Sales per Capita by State

  • Sales per Capita and State Rankings

Page 14 – Sales as a Percent of Income by State

  • Sales as a % of Income and State Rankings

Page 15 – Sales per Establishment by State

  • Sales per Establishment and State Rankings

Page 16 – Pricing & Inflation

  • Annual Inflation – Indexed to 2006
  • 2010-2018 Historical Figures
  • Forecasts 2019 and the Next 5 Years
  • Monthly Inflation Figures for the Past 4 Years

Page 17 – Consolidation Analysis

  • Number of Firms by Size of Firm
  • Number of Establishments by Size of Firm
  • Establishments per Firm by Size of Firm
  • 2012 versus 2018

Page 18 – Employment by Firm Size

  • Number of Employees by Firm Size
  • Employees per Firm by Size of Firm
  • Employees per Establishment by Size of Firm
  • 2012 versus 2018

Page 19 – Manufacturing Subsector Consolidation Analysis

  • Number of Firms
  • Number of Establishments
  • 5 Year CAGR

Page 20 – Manufacturing Subsector Consolidation Analysis

  • Establishments per Firm
  • Employees per Firm
  • 5 Year CAGR

Section Two


Page 22 – Profitability & Financial Ratio Analysis

  • Percent of Companies that are Profitable
  • Average Net Income as a Percent of Revenue
  • Financial Ratios – 10 ratios, such as Total Asset

Turnover, Assets to Liabilities, Return on Net Worth, Solvency Ratio

Page 23 – Operating Expenses

  • Industry Operating Expenses
  • Industry Revenue vs. Operating Expense Growth
  • Operating Expense as a Percent of Revenue
  • 2010-2018 Historical Figures
  • Forecasts 2019 and the Next 5 Years

Page 24 – Operating Expenses by Firm & Establishment

  • Operating Expenses per Firm
  • Operating Expenses per Establishment
  • Revenue vs. Expenses Growth per Establishment
  • 2010-2018 Historical Figures
  • Forecasts 2019 and the Next 5 Years

Page 25 – Operating Expense Detail

  • Employee Expenses
  • Property Expenses
  • Equipment Expenses
  • IT Expenses
  • Inventory Handling & Supplies Expenses
  • Miscellaneous Expenses

Page 26 – Productivity & Industry Employment

  • Revenue per Employee
  • Total Industry Employees
  • Employees per Firm
  • 2010-2018 Historical Figures
  • Forecasts 2019 and the Next 5 Years

Page 27 – Employee Productivity by State

  • Revenue per Employee and State Rankings

Page 28 – Industry Payroll

  • Payroll per Employee
  • Payroll per Firm
  • Payroll per Establishment
  • 2010-2018 Historical Figures
  • Forecasts 2019 and the Next 5 Years

Page 29 – Payroll by Size of Firm

  • Payroll per Firm
  • Payroll per Establishment
  • Payroll per Employee
  • 2012 versus 2018

Page 30 – Payroll per Employee by State

  • Payroll per Employee and State Rankings

Page 31 – Job Categorization Benchmarks

  • Management & Finance
  • Sales & Marketing
  • Technology, Engineering, Science
  • Service, Support & Training
  • Operations
  • Percent of Industry Employees

Page 32 – Job Categorization Pay Ranges

  • Management & Finance
  • Sales, Service & Marketing
  • Operations
  • Pay Bands – Bottom 10% & 25%, Mean, Top 25% & 10%

Page 33 – Top 20 Jobs Breakdown

  • Percent of Total Employees

Page 34 – Top 20 Jobs Pay

  • Pay Bands – Bottom 10% & 25%, Mean, Top 25% & 10%

Page 35 – Total Employment by State

  • Number of Employees and State Rankings

Page 36 – Population to Every Employee by State

  • Number of Residents to Industry Employee
  • State Rankings

For more information about this report visit

Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Household

Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493


Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits




HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.   

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.

Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.   

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025


Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.


Cision View original content:

Continue Reading


Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer




DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.

Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.

“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected] 

View original content:

Continue Reading


Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028



Continue Reading

Trending on Grassnews Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania